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Abstract
Recent in vitro evidence shows that glycosaminoglycans (GAGs) and proteoglycans (PGs) in bone matrix may
functionally be involved in the tissue-level toughness of bone. In this study, we showed the effect of biglycan
(Bgn), a small leucine-rich proteoglycan enriched in extracellular matrix of bone and the associated GAG subtype,
chondroitin sulfate (CS), on the toughness of bone in vivo, using wild-type (WT) and Bgn deficient mice. The
amount of total GAGs and CS in the mineralized compartment of Bgn KO mouse bone matrix decreased significantly, associated with the reduction of the toughness of bone, in comparison with those of WT mice. However,
such differences between WT and Bgn KO mice diminished once the bound water was removed from bone
matrix. In addition, CS was identified as the major subtype in bone matrix. We then supplemented CS to both WT
and Bgn KO mice to test whether supplemental GAGs could improve the tissue-level toughness of bone. After
intradermal administration of CS, the toughness of WT bone was greatly improved, with the GAGs and bound
water amount in the bone matrix increased, while such improvement was not observed in Bgn KO mice or with
supplementation of dermatan sulfate (DS). Moreover, CS supplemented WT mice exhibited higher bone mineral
density and reduced osteoclastogenesis. Interestingly, Bgn KO bone did not show such differences irrespective
of the intradermal administration of CS. In summary, the results of this study suggest that Bgn and CS in bone
matrix play a pivotal role in imparting the toughness to bone most likely via retaining bound water in bone matrix.
Moreover, supplementation of CS improves the toughness of bone in mouse models.
© 2020 The Author(s). Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/)

Introduction
Osteoporosis and bone fragility fractures are a
major concern of health care for our rapidly growing
aging population. Although the current common consensus is that the fracture risk is mainly dependent
on bone mineral density (BMD) [1], more recent evidence shows that BMD alone lacks sensitivity to
evaluate the mechanical performance of bone accurately [24]. This is likely, in part, because bone is a
hierarchical composite of mineralized type I collagen
fibrils embedded in a matrix of non-collagenous proteins (NCPs) and hydroxyapatite mineral phase [5].

In the past, extensive efforts have been made to
study the contribution of the mineral and collagen
phases to the mechanical competence of bone
[610]. It was not until recently that the direct effect
of NCPs on bone mechanical properties has started
to attract more attention [1113]. Proteoglycans
(PGs) are a set of the structural NCPs in bone extracellular matrix, which have strong affinity to both collagen and mineral crystals [14,15]. Typically, PGs
contain glycosaminoglycans (GAGs) chains, which
are long unbranched polysaccharides comprising a
series of repeating disaccharide unit, attached to
core proteins [16]. GAGs are highly negatively
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charged, thus possessing a great osmotic potential
to attract water into the matrix, while matrix water
has been reported to function as a critical mediator
to facilitate the plastic deformation of bone at both
bulk and ultrastructural levels [1722]. However,
the role of PGs and GAGs in regulating mechanical
behavior of bone remains poorly investigated [23].
Our previous in vitro studies using human cadaveric bone samples showed that PGs and GAGs
might play an important role in sustaining bone
toughness via retaining bound water in the matrix
[24,25]. The studies also showed that loss of chondroitin sulfate (CS), a major subtype of GAGs in
bone matrix, was associated with age-related deterioration of bone toughness. It has been reported that
biglycan (Bgn) is a major subtype of CS-containing
PGs and is highly expressed in bone tissues
[2628]. Bgn has two Ser-Gly attachment sites in
the N-terminal region and belongs to the class I type
small leucine-rich PGs (SLRPs), which are characterized by relatively small protein cores (36-42 kDa)
harboring tandem leucine rich repeats [2931].
The current understanding of effects of Bgn on
bone is mainly focused on its biological aspects.
Studying mice with targeted Bgn disruption has
revealed the involvement of Bgn in the regulation of
postnatal skeletal growth. Bgn deficiency may lead
to decreases in bone mass, bone mineral density,
long bone length, and bone biomechanical strength
compared to age-matched controls [32]. Histological
analysis indicates that Bgn KO mice may have less
trabecular volume and thinner cortices. Bgn deletion
may cause structural abnormalities of bone collagen
fibrils and impair the metabolic activity of bone marrow stromal cells (BMSCs) [33,34]. However, it is still
unclear whether Bgn depletion in vivo would lead to
loss of bound water in bone matrix and subsequently
result in deterioration of bone toughness.
The aim of this study was to investigate the specific role of Bgn in retaining bound water in bone
matrix and maintaining bone toughness using a
Bgn-deficient mouse model. Biochemical, biophysical, and biomechanical experiments were performed
to determine the amount of total GAGs, CS and
bound water in bone matrix, and their effects on the
tissue-level toughness of bone. In addition, this
study investigated the effect of matrix Bgn on the
efficacy of supplemental CS in improving bone
toughness in vivo using the mouse model.

blotting analysis using an anti-Bgn antibody. The
Bgn protein band under both glycosylated (Fig. 1A)
and deglycosylated (Fig. 1B) conditions can be
detected in the mineralized bone lysates of WT
mice, with a Bgn protein band shift observed after
the treatment by deglycosylation enzyme mix to
remove both N-linked and O-linked glycans. Compared to WT samples, the expression of Bgn was
abolished in both non-treated and deglycosylated
groups of Bgn knockout (KO) mice, with comparable
amount of total protein loaded on the gel as shown
by Ponceau S staining (Fig. 1A and B, left panels).
Consistently, immunohistochemistry staining of Bgn
protein in paraffin sections prepared from WT and
Bgn KO mice showed that the expression of Bgn
was abundant in cell bodies of osteocytes in WT
mice (Fig. 1C, left panel, black arrows), while only
background signal could be detected in the sections
from Bgn KO mice (Fig. 1C, middle panel). Rabbit
IgG was used as an isotype control (Fig. 1C, right
panel), showing no reactivity.
We next examined whether there would be a
reduction of the GAGs amount induced by Bgn deficiency, as Bgn is one of the major PGs in bone
matrix that contain the GAGs [27,28,35]. The level of
total GAGs was determined by DMMB assay in both
mineralized and non-mineralized compartments of
bone. Consistent with our previous observations in
human bone study [24], GAGs were mainly present
in the mineralized portion of mouse bone matrix.
Compared with WT mice, Bgn KO mice showed a
significant decrease in total GAGs amount in the
mineralized matrix, while the difference was not evident in the non-mineralized compartment (Fig. 1D).
To further validate the GAGs changes under Bgn
deficiency condition, bone sections prepared from
the mid-diaphysis of WT and Bgn KO mice were
stained with Alcian blue. The stained GAGs were
visible around the osteocytes and throughout
the lacunar-canalicular network in bone matrix
(Fig. 1E, left panel). Quantification of the Alcian
blue staining by integrating the intensity over of
the area of interest indicated a significant reduction of GAGs content in Bgn KO mice (Fig. 1E,
right panel). These results suggest that amount of
total GAGs in bone matrix decreases with the loss
of Bgn in bone matrix.

Results

The coupling effect of proteoglycans and bound
water in maintaining bone toughness has been
shown in human bone during the aging process
[24,25]. To examine the effects of Bgn deficiency
on the amount of bound water, cortical bone
lysates of WT and Bgn KO mice were analyzed by
low-energy NMR measurements. Results showed
that the index of bound water was 0.55§0.02 in

Biglycan deﬁciency induces reduction of total
glycosaminoglycans in bone matrix
PGs isolated from bone matrix of 6-month-old WT
and Bgn KO mice were subjected to Western

Biglycan deﬁciency decreases amount of bound
water and bone toughness
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Fig. 1. Bgn KO mice showed decreased amount of total GAGs in bone. (A) Proteoglycans from WT and Bgn KO mice
mineralized bone matrix were analyzed by western blots probed with anti-Bgn antibody (right panel). Ponceau S staining
showed comparable sample loading from WT and Bgn KO mice (left panel). The asterisk (*) denotes non-specific bands.
(B) Proteoglycans from WT and Bgn KO mice mineralized bone matrix were treated with deglycosylation enzyme mix to
reveal the Bgn core protein, and were analyzed by western blots probed with anti-Bgn antibody (right panel). Ponceau S
staining showed comparable sample loading from WT and Bgn KO mice (left panel). The asterisk (*) denotes non-specific
bands. (C) Paraffin sections of femoral cortical bone from WT (left panel) and Bgn KO mice (middle panel) were immunolabeled with anti-Bgn antibody. The positive signals (brown) were labeled by black arrows. Rabbit IgG was used as isotype control (right panel). Scale bar, 20 mm. (D) The total GAGs amount from mineralized (left panel) and non-mineralized
(right panel) compartments of WT and Bgn KO mice bone matrix was quantified by DMMB assay. (E) WT and Bgn KO
mice paraffin-embedded bone tissue sections were stained with Alcian blue (left panel). Scale bar, 50 mm. The integrated
density of the staining was analyzed by NIH Image J software (right panel). n = 5-6. * p < 0.05.

WT mice bone, and 0.48§0.02 in Bgn KO mice,
exhibiting a significant reduction in bound water in
bone matrix (Fig. 2A). We next investigated the tissue-level toughness determined by nanoscratch
test using bone samples from the mid-diaphyseal
femurs of WT and Bgn KO groups. Under the wet
condition, in which the samples were soaked in
PBS solution during the test, the tissue-level
toughness of bone decreased significantly for Bgn
KO mice compared to WT mice (Fig. 2B). However,
under the dry condition, in which the bound water
in bone matrix was removed by heating, the

change in the tissue-level toughness induced by
Bgn deficiency was totally abolished. In addition,
dehydration had a profound effect on the toughness of WT bone when comparing between the
wet and dry conditions. Noticeably, Bgn KO mice
also showed reduction of tissue-level toughness
after dehydration, indicating the potential involvement of other factors in retaining water in the bone.
Taken together, we concluded that Bgn is one of
the PGs in bone mineral matrix that plays a key
role in retaining water and sustaining the toughness of bone.
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Fig. 2. Bgn KO mice showed decreased amount of
bound water and bone toughness. (A) The amount of
bound water in WT and Bgn KO mice bone matrix was
measured by low-field NMR. (B) The femoral cortical samples from WT and Bgn KO mice were subjected to a nanoscratch test for tissue-level toughness at mid-diaphysis.
Bone toughness was determined under wet (normal) condition and dry bone condition with dehydration to remove
the bound water in bone matrix. n = 6-7. * p < 0.05;
** p < 0.01; *** p < 0.001.

degradation of polysaccharides containing (1-4)b-D-hexosaminyl and (1-3)-b-D-glucuronosyl or
(1-3)-a-L-iduronosyl linkages to disaccharides containing 4-deoxy-b-D-gluc-4-enuronosyl groups. After
chondroitinase ABC digestion, bands of CS, DS and
GAGs isolated from mouse bone disappeared, further suggesting that the majority of GAGs in mineralized matrix is in the form of CS.
In order to determine the change of CS band intensity under Bgn deficiency condition, GAGs from both
non-mineralized (non-M) and mineralized compartments of WT and Bgn KO mice bone were analyzed
by agarose gel electrophoresis. GAGs from equal
weight of bone samples were loaded on the gel.
There were no detectable GAG forms in the non-mineralized portion in both the WT and Bgn KO mice
bone matrix (Fig. 3B, left panel). Densitometry measurements revealed that CS band intensity was significantly lower in the Bgn KO mice than in the WT mice
(Fig. 3B, right panel), suggesting that Bgn deficiency
may lead to decrease of CS in bone matrix.

Chondroitn sulfate is the major
glycosaminoglycan subtype in bone mineral
matrix and is decreased under biglycan
deﬁciency condition

Chondroitin sulfate supplement improves GAGs
and bound water amount, tissue-level
toughness, and bone mineral density in WT
mice, but not in Bgn KO mice

GAGs extracted from WT mice bone mineralized
matrix were analyzed by agarose gel electrophoresis. In addition, the in situ visualization of GAGs was
realized via toluidine blue staining. Pure heparin sulfate (HS), dermatan sulfate (DS) and CS were
served as standard controls. WT mice bone showed
a single band of GAGs aligned with the CS population (Fig. 3A). Chondroitinase ABC specifically
degrades CS and DS by catalyzing the eliminative

We have previously reported that GAGs amount
decreases with aging and is associated with deterioration of bone toughness in human cadaveric bone
samples [24]. Considering that CS is the major form
of GAGs in bone and Bgn depletion may lead to a
decreased toughness of the tissue, we investigated
if supplementing CS in vivo would improve the
toughness of middle-aged mice bone. Based on the
life phase equivalencies between mouse and

Fig. 3. Chondroitin sulfate is identified as a major GAG subtype in the mineral matrix of mouse bone and is reduced in
Bgn KO mice. (A) Agarose gel electrophoresis showed various subtypes of GAGs, heparin sulfate (HS), dermatan sulfate
(DS), and chondroitin sulfate (CS). GAGs extracted from WT mouse bone matrix were examined and confirmed by chondroitinase ABC digestion. (B) GAGs from non-mineralized (Non-M) and mineralized (Mineral) compartments of WT and
Bgn KO mice bone matrix were analyzed by agarose gel electrophoresis. CS was detected in mineralized bone matrix
(left panel). The CS band intensity was quantified by NIH Image J software (right panel). n = 6-7. * p < 0.05.
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human, we selected middle-aged mice around 10 to
11-month-old for CS supplementation study. We
administrated CS intradermally at the base of the
mouse tail, since a previous study has reported
intradermal injection of CS and its incorporation into
mouse tissues [36]. CS (European pharmacopoeia
reference standard) was injected once a week for 4
weeks. The amount of GAGs in mineralized and
non-mineralized cortical bone matrix of both WT and
Bgn KO mice was determined.
The results showed that supplementation of CS
significantly increased the GAGs amount in the mineralized portion of WT bone matrix; while the GAGs
amount in non-mineralized matrix of WT bone was
not affected when compared with saline controls
(Fig. 4A). Interestingly, administration of CS
appeared to have no effect on the amount of GAGs
in both non-mineralized and mineralized bone matrix
for Bgn KO mice (Fig. 4E). We next examined the
level of bound water from both WT and Bgn KO
mice bones treated with saline or CS. As shown in
Fig. 4B, compared to saline control group, supplementation of CS significantly increased the amount
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of bound water in WT mice. In contrast, the Bgn KO
mice did not exhibit any difference of bound water
amount after CS injection (Fig. 4F).
We then measured the tissue-level toughness of
bone for WT and Bgn KO mice with CS or saline
injections by the nanoscratch test. The results
showed a significant improvement of bone toughness in WT mice supplemented with CS compared
to controls with saline injection (Fig. 4C). However,
no difference existed in the tissue-level toughness
between CS and saline injected Bgn KO mice
(Fig. 4G). These results further suggested the importance of GAGs in retaining bound water and conferring tissue-level toughness into the bone. The
whole-body total bone mineral density (BMD) was
determined before and after saline or CS injection. A
significant elevation of BMD was observed in the
WT mice injected with CS compared with those
injected with saline alone (Fig. 4D), while the Bgn
KO group did not exhibit any significant BMD
increase after CS supplementation (Fig. 4H).
Further, we tested whether other types of GAGs
would have a similar effect on bone in WT mice.

Fig. 4. Chondroitin sulfate supplementation improved GAGs amount, bone mineral density (BMD) and tissue-level
toughness in WT mice, but not in Bgn KO mice. (A) Total GAGs amount from mineralized (left panel) and non-mineralized
(right panel) compartments of saline or CS injected WT mice bone matrix was quantified by DMMB assay. (B) After saline
or CS injection, the amount of bound water in WT mice bone matrix was measured by low-field NMR, and normalized by
comparing to saline controls. (C) Tissue-level toughness of femur mid-diaphysis from saline or CS injected WT mice was
determined by nanoscratch test. (D) Total BMD was measured by DXA analysis at pre-injection and after injection with
saline or CS. Total BMD change was obtained by calculating the ratio of total BMD before and after injection, and then
normalized by comparing to saline controls. (E-H) The total GAGs amount, bound water, tissue-level toughness, and normalized BMD change were analyzed in Bgn KO mice after injection of saline or CS. n =5-9. * p < 0.05.

100

Biglycan and chondroitin sulfate play pivotal roles in bone toughness via retaining bound water

Fig. 5. Supplementation of dermatan sulfate did not change the GAGs amount, bone mineral density (BMD) in WT
mice. (A) Total GAGs amount from mineralized (left panel) and non-mineralized (right panel) compartments of saline or
DS injected WT matrix was quantified by DMMB assay. (B) Total BMD was measured by DXA analysis at pre-injection
and after injection with saline or DS. Total BMD change was obtained by calculating the ratio of total BMD before and after
injection, and then normalized by comparing to saline controls. (C) Tissue-level toughness of femur mid-diaphysis from
saline or dermatan sulfate injected WT mice was determined by nanoscratch test. n =5-6.

Since dermatan sulfate (DS) is another major type of
GAGs and has been shown to attach to Bgn core
protein, we administrated DS (United States pharmacopeia reference standard) in middle-aged WT
mice adopting the same strategy for supplementing
CS. The results showed that the total amount of
GAGs did not change in both mineralized and nonmineralized bone matrix after DS injection (Fig. 5A).
In addition, the whole body BMD and tissue-level
toughness did not show any significant difference
between DS injected WT mice and saline controls
(Fig. 5B and C). Together, these results suggest that
administration of CS may increases the amount of
GAGs and bound water in bone matrix, BMD, and
tissue-level toughness of bone in WT mice, but this
increase was not shown in Bgn KO and DS supplemented WT mice.

Chondroitin sulfate supplement inhibits
osteoclast activation in WT mice, but not in Bgn
KO mice
To further investigate the bone phenotypes of CS
or saline injected WT and Bgn KO mice, we performed tartrate-resistant acid phosphatase (TRAP)
staining for osteoclastogenesis analysis. The osteoclasts were visualized and quantified in endocortical
femoral bones. The results showed that supplementation of CS significantly attenuated osteoclast activation in WT mice (Fig. 6), showing reduced
osteoclast surface (Oc.S) normalized to bone surface (Oc.S/B.S) compared to saline group, while no
difference was observed in Bgn KO mice.
In addition, bone dynamic histomorphometry
parameters were analyzed using a calcein and

Fig. 6. Chondroitin sulfate injection decreased osteoclast surface in endocortical bone of WT mice. (A) Representative
images of TRAP stained paraffin sections from WT and Bgn KO mice femoral bones after saline or CS injection. Yellow
arrow heads indicate TRAP positive osteoclasts. Scale bar, 50 mm. (B) Quantification of Oc.S/B.S in saline or CS injected
WT and Bgn KO mice bones. n =5-7. * p < 0.05. B.S, bone surface; OC.S, osteoclast surface; TRAP, tartrate-resistant
acid phosphatase.
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Fig. 7. Supplementation of chondroitin sulfate did not
change bone dynamic histomorphometry parameters in
endocortical bone of WT and Bgn KO mice. (A) Representative images of plastic sections prepared from CS or
saline injected WT and Bgn KO mice. Scale bar = 50 mm.
Mice were injected twice with calcein and alizarin red S
dyes for dynamic histomorphometry. (B-D) Endocortical
MAR, MS/BS, and BFR/BS were measured in unstained
sections from the femoral mid-diaphysis. * p < 0.05. n = 58. MAR, mineral apposition rate; BFR, bone formation
rate; BS, bone surface; MS, mineralizing surface.

alizarin double labeling assay. As shown in Fig. 7,
the endocortical bone mineral apposition rate (MAR)
and bone formation rate (BFR/BS) of saline injected
Bgn KO mice were decreased compared to WT
saline group, which is consistent with a previous
report showing inhibited bone formation in Bgn KO
mice [32]. However, compare to saline group, minimal effects of CS on bone formation were exhibited
in WT and Bgn KO mice. These results suggested
the anti-catabolic function of CS supplementation in
WT mouse bone.

Discussion
Hydration status significantly affects bone
strength and toughness. Synchrotron X-ray scattering and other studies show that the nanomechanics
of bone is significantly dependent on the bound
water in bone matrix and that the bound water
resid
ing in small ultrastructural spaces (< 4.0A) dictates
the mechanical behavior of bone by altering the
interaction among hydroxyapatite (HA) crystals and
their surrounding matrix [20,37]. Recent evidence
indicates that PG/GAGs in the organic interface of
extrafibrillar matrix may impart toughness to bone by
attracting and retaining water in the matrix [24,25].
However, the key PG/GAGs involved in this process
remained unidentified. In this study, using the Bgndeficiency mouse model, we found that Bgn and CS,

101

which are major components of PGs and GAGs in
the extrafibrillar matrix of bone, respectively, played
a pivotal role in the regulation of tissue-level hydration status and toughness of bone. This finding supports the hypothesis that PG/GAGs help attracting
water into the organic interface between mineral
crystallites, thus facilitating the ductile deformation
of bone (Fig. 8).
The unreliable prediction of bone fracture by using
BMD alone has raised the necessity of elucidating
the ultrastructural and molecular origins of bone fragility in order to better predict and prevent bone fragility fractures. Previous studies have shown that
water plays a critical role in sustaining the toughness
of bone [3739]. In addition to Type I collagen that
constitutes 90% of organic phase and serves as a
major site in bone that retains bound water, NCPs
also possess a great capacity to attract water.
Among NCPs, GAGs of PGs are highly electrically
charged carbohydrate chains and interact with each
other in a head to tail manner, forming interfibrillar
supramolecular assemblies that could absorb water
into the extracellular matrix of bone [40]. The contribution of PGs and GAGs to mechanical behavior of
connective tissues, particularly soft tissues, such as
tendon, articular cartilage and intervertebral disks,
has been well documented [4146]. However, the
contribution of PGs to the mechanical behavior of
mineralized tissues remains largely elusive. At the
microscale, PGs may regulate the hydrostatic and
osmotic potential, as well as poroelastic behavior of
dentine and bone [23,47]. Our previous studies indicated the coupling effect of water and PGs on the
toughness of bone by removing N-linked oligosaccharides enzymatically from the bone matrix in vitro
[25]. In addition, Ho et al reported in an in vitro study
that the removal of GAGs decreased the hardness
and elastic modulus of cementum-dentin junction
[48]. Moreover, the age-related loss of GAGs was
reported to associate with the deterioration of bone
toughness and the decreased amount of Bgn using
an ex vivo model [24]. The results of this in vivo
study again verify the previous findings, showing
that PGs is coupled with bound water to toughen
bone matrix by imparting ductility to the tissue.
As a member of the SLRPs family, Bgn is distributed abundantly throughout the cortical and trabecular bone matrix [49]. SLRPs play crucial roles in
bone formation by regulating cell proliferation, matrix
deposition and remodeling [5054]. A Bgn deficient
mouse model was first described by Xu et al, (1998)
exhibiting age-dependent osteopenia compared to
WT counterparts [32]. Disruption of Bgn also leads
to structural abnormalities in bone collagen fibrils
and metabolic defects in BMSCs [33,34,55]. Subsequent investigations identified that Bgn binds TGF-b
and controls its bioactivity [56,57], modulates
BMP4-induced osteoblast differentiation [58], and
affects the Wnt signaling pathway [59]. The four-
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Fig. 8. Schematic summary of the role of Bgn and CS in water retention in extracellular bone matrix and bone toughness. Structurally, bone is comprised of mineralized collagen fibrils embedded in bone extrafibrillar matrix. These mineral
crystals are bounded through organic interface of non-collagenous proteins and bound water. Bgn belongs to small leucine-rich proteoglycans with two sulfate chains and has a great potential to absorb water into the matrix. With deficiency
of Bgn in knockout mouse model, there was a decreased amount of CS, total GAGs and bound water in bone matrix,
along with the compromised bone toughness due to impaired water retention capability.

point bending test of Bgn KO mice bone showed
reduced failure load and yield energy after 6 months
of tissue development [32]. In this study, the nanoscratch test exhibited decreased tissue-level toughness of bone for 6-month-old Bgn deficiency mice,
which is in good agreement with the impaired
strength and ductility observed in the previous study,
indicating the correlation of tissue-level and bulk
mechanical properties. These results provided direct
evidence for the mechanical contribution of PGs/
GAGs in bone tissue.
Comprising about 20% of the volume, water is a
key determinant of the mechanical behavior of bone,
showing that loss of bound water correlates strongly
with bone toughness deterioration [38,39,60]. Similarly, this study also showed a significant reduction
of tissue-level toughness of bone in WT mice after
removal of bound water, whereas such changes
induced by removal of bound water were significantly reduced in Bgn KO mice. Under the dehydrated condition, the tissue-level toughness of bone
is consistent between Bgn KO mice and WT controls. The results suggest that the coupling effect of
water and PGs in sustaining the toughness of bone
is disrupted once Bgn is removed from the matrix.
However, it is noteworthy that the effect of bound

water on the tissue-level toughness of bone still
exists in Bgn KO mice, raising the possibility of the
involvement of other PGs or non-PG factors in this
process.
Bgn and decorin (Dcn) are considered as major
PGs in the mineralized bone matrix. They share
57% identity at the amino acid level and are coexpressed in bone [29,30]. The studies of Dcn/Bgn
double KO mice show that the skin tissue is much
thinner and fragile than either single Bgn KO or single Dcn KO animals, and the osteopenia of the double KO mice is also more severe than the single
Bgn KO mice [33,61]. Furthermore, Dcn protein
level is higher in Bgn deficient tissues [62]. In osteoblasts with Bgn KO, Dcn accumulated to higher levels and localized unevenly in the extracellular matrix
compared to the WT cell cultures [58]. These previous reports suggest a potential compensation and
synergistic function between Bgn and Dcn [63].
Moreover, a recent report indicates that Bgn and
another SLRPs, fibromodulin, are novel coupling
components regulating osteoclastogenesis [64].
Since only Bgn KO mice were used in this study, it
is possible that Dcn would replace some functions of
Bgn to compensate the loss of structural integrity of
bone matrix induced by Bgn depletion. Therefore, it
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is anticipated that depletion of both Bgn and Dcn
would result in much larger changes in bone
mechanical properties.
Both Bgn and Dcn contain CS or DS side chains,
and the attachment of CS versus DS is tissue-specific [53]. Classically, CS is predominantly attached
to Bgn and Dcn within mineralized tissues, such as
dentine and bone, whereas DS is mainly associated
with soft connective tissues [50]. The agarose electrophoresis results of this study indicated that only
CS appeared in mouse bone matrix, without noticeable presence of HS and DS. This observation
implies that CS is the major GAGs in mouse bone
matrix, although the minor presence of other GAGs
still cannot be excluded.
The supplementation of CS to WT mice appeared
to increase the total amount of GAGs and bound
water in bone matrix, the whole body BMD, and the
tissue-level toughness of bone. However, CS
administration did not improve the mechanical properties of bone of Bgn KO mice. On the other hand,
the DS supplementation seemed to have little effects
on bone in the WT mice, which again underscores
the predominant function of CS in bone matrix. In
addition, bone histomophormetry studies indicated
the decreased catabolic response in CS injected
WT mice revealed by inhibited osteoclastogenesis,
resulting in the net bone increase.
Previous study by Chen et al reports that Bgn
deficiency blunts BMP-4 induced osteoblast differentiation in vitro [58]. The absence of Bgn decreases
BMP-4 sensitivity caused by less BMP-4 binding,
and is completely rescued by viral transfection of
Bgn. A later study further highlights the importance
of GAG chains of Bgn in modulating osteoblast differentiation, showing the expression of a mutant
Bgn lacking GAGs binding sites cannot rescue the
differentiation deficiency [65]. In contrast to the inhibition of osteoblastogenesis, Bgn KO mice did not
show any difference in bone resorption compared to
WT mice, which has been reported in previous study
[32] and was also observed in our results. However,
it is interesting to note that Bgn KO exacerbates
LPS induced osteolysis and bone resorption in vivo
[66]. In vitro co-culture of osteoblasts and osteoclasts shows that Bgn deficiency increases osteoclast differentiation through its effect on osteoblasts.
In our study, Bgn KO mice did not respond to CS
injection induced GAGs elevation in bone matrix,
which was probably attributable to less binding of
CS under the condition of Bgn deficiency. Considering the role of highly negatively charged GAGs in
retaining bound water, lack of increase in GAGs
amount led to blunted bound water and thus
reduced bone toughness. However, the direct evidence of CS binding ability under Bgn KO condition
remains to be further investigated. In addition, since
bone mass is maintained by a balance between
bone formation and bone resorption, the lack of
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response to CS induced anti-catabolic effects may
be due to the defective osteoblasts in Bgn KO mice.
The results of this study demonstrate the pivotal role
of Bgn and CS in bone toughness and homeostasis.
The anti-catabolic function of CS has been demonstrated in both chondrocytes and osteoblasts [6769].
CS upregulated OPG production, while reduced
RANKL expression, leading to a significantly higher
OPG/RANKL ratio, which could exert a positive outcome for bone. Additionally, CS has direct function on
osteoclasts, showing inhibition of osteoclast differentiation, and osteoclast-specific expression of TRAP and
cathepsin K [70,71]. A recent in vivo study using CS
treatment for diabetic osteoporosis reveals the
increased bone-mineral density, repaired bone morphology and decreased femoral osteoclasts [72], which
is in good agreement with our findings.
In fact, Bgn could serve as a potential therapeutic
target, and administration of CS, possibly locally,
may be a viable treatment strategy for osteoporosis
and fracture healing. For instance, previous evidence shows that modulation of Bgn gene expression may counteract bone loss under an estrogen
depletion condition [73]. Interestingly, oral administration of GAGs as nutritional supplements is controversial. CS has been widely consumed orally as a
nutraceutical with applications in the therapy of osteoarthritis, which is mostly administered at doses
ranging from 800 to 1200mg/day [74]. However, CS
can be rapidly absorbed by the gastrointestinal system, with the overall bioavailability of CS ranges
from 10% to 20% following oral administration
[75,76]. Additionally, most of the absorbed CS
reaches the blood compartment as depolarized lowmolecular weight derivatives [77]. Our study used
intradermal injection for CS administration, which
could avoid the extensive first pass metabolism in
the gastrointestinal tract prior to systemic availability, thus resulting in a much higher plasma concentration as shown in the previous studies using
intravenously injection of CS [78].
In conclusion, our findings indicated that Bgn deficiency would lead to loss of CS, GAGs, and bound
water in bone matrix, thus leading to the deterioration of the tissue-level toughness of bone. In addition, CS supplementation showed a potential in
improving the toughness of bone, thus opening an
additional avenue for developing new therapeutics
in improving bone quality.

Materials and methods
Animals
The Bgn KO mice were originally generated by
homologous recombination in embryonic stem cells
as described elsewhere [32] and were generously
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provided by Marian F. Young (National Institutes of
Health, Bethesda, MD, USA). All experiments were
performed using age-matched WT (Bgnþ/0, Bgn is
on X chromosome) and Bgn deficient (Bgn/0) male
mice, since Bgn deficiency, shows a minor effect on
bone metabolism in female mice [73]. The genotype
of the WT and Bgn KO mice was determined by a
PCR-based assay [33]. The generated DNA fragments of 212 bp and 310 bp represent the WT and
targeted Bgn allele, respectively.
For chondroitin sulfate (CS) supplementation
experiments, 10 to 11-month-old WT and Bgn KO
male mice were injected intradermally at the base of
the tail with 4 mg/kg CS (Y0000280, Sigma-Aldrich,
St. Louis, MO, USA) dissolved in saline and filtered.
Control mice were injected with the same volume
saline. Injections were given once a week for four
weeks. All mice used were of C57BL/6 background.
The mice were housed in a temperature-controlled
room with a light/dark cycle of 12 hours at the
UTHSCSA Institutional Lab Animal Research (LAR)
facility, under specific pathogen-free conditions.
Food and water were provided ad libitum. All animal
protocols were performed in accordance with the
National Institutes of Health guidelines for care and
use of laboratory animals. The animal protocols
were approved by the UTHSCSA Institutional Animal Care and Use Committee.
Extraction and quantiﬁcation of
glycosaminoglycans from bone tissues
The long bones (e.g. femur, tibia, humerus, and
radius) were isolated free of soft tissues and bone
marrow was removed by flushing with cold PBS by
drilling a hole on both ends of the bones. GAGs
were isolated from the non-mineralized (e.g.,
osteoids, membranes, and bone surfaces) and mineralized compartments in bone matrix, respectively
[7981]. Briefly, cortical bone tissues were crushed
to fine powders with the pestle in a mortar filled with
liquid nitrogen. The bone powders were first treated
in lysis buffer I (4 M guanidine HCl, 0.05 M Tris, and
0.1 M 6-aminocaproic acid, pH 7.4) containing proteinase inhibitors at 4°C on the orbital shaker for
72 hours to remove GAGs from the non-mineralized
compartment of bone. The carefully rinsed bone
powders were treated in lysis buffer II (4 M guanidine
HCl, 0.5 M EDTA tetrasodium salt, 0.05 M Tris, and
0.1 M 6-aminocaproic acid, pH 7.4) containing proteinase inhibitors at 4°C on the orbital shaker for
72 hours to remove GAGs from the mineralized
compartment of bone. The supernatant from each
treatment was collected and the amount of GAGs
was quantified by dimethylmethylene blue (DMMB)
assay as follows: 50 mL samples and 200 mL
DMMB mix (46 mM DMMB (Sigma-Aldrich, St.
Louis, MO, USA), 40 mM NaCl, and 40 mM glycine,
pH adjusted to 3.0 with acetic acid). The above

solution was pipetted into 96-well plates and shake
for 5 seconds. The absorbance was recorded at
wavelength 525 nm. The amount of GAGs was
determined by comparing with the standard curves
generated using purified GAGs (Sigma-Aldrich, St.
Louis, MO, USA).
Chondroitinase ABC digestion of
glycosaminoglycans
Chondroitinase ABC from Proteus vulgaris
(C3667, Sigma-Aldrich, St. Louis, MO, USA) were
reconstituted in 0.01% bovine serum albumin aqueous solution. The extracted GAG samples were
incubated in 1 U/mL chondroitin ABC lyase or MilliQ
water in freshly prepared digestion buffer (50 mM
Tris, pH 8.0, 60 mM sodium acetate and 0.02%
bovine serum albumin) overnight at 37°C. Digestion
control samples: heparin sulfates (HS), dermatan
sulfates (DS) and chondroitin sulfates (CS)
extracted from shark cartilage (1 mg/mL) were incubated in chondroitin ABC lyase or MilliQ water overnight at 37°C and digested samples were analyzed
by agarose gel electrophoresis.
Agarose gel electrophoresis
GAGs isolated from non-mineralized and mineralized bone samples as well as GAGs standards, HS,
DS and CS were separated by 0.9% agarose gel
electrophoresis in 1,3-propanediamine acetate
buffer (50 mM, pH 9.0) for 90 min at 80V. Following
the electrophoresis, the GAGs were fixed using
0.2% (w/v) cetyl-trimethyl-ammonium bromide
(CTAB) solution for 1 hour at room temperature, and
then the gels were dried. Gels were stained with
0.1% (w/v) toluidine blue prepared in solution of
50% (v/v) ethanol, 49% (v/v) water and 1% (v/v)
water, and destained in the same solution without
toluidine blue.
Western blotting
Protein concentrations of proteoglycans extracted
from mineralized matrix of mice cortical bone samples
were determined by Micro BCA Protein Kit (Thermo
Scientific, Rockford, IL, USA). Equal amount of proteins determined by microBCA assay was treated
with or without Protein Deglycosylation Enzyme mix
(P6044, New England Biolabs, MA, USA) for 1 hour
at 37°C following the manufacturer’s instructions. Protein Deglycosylation Enzyme Mix contains PNGase
F, O-glycosidase, neuraminidase, b1-4-galactosidase, and b-Nacetylglucosaminidase, which can
completely remove glycosylation. Each protein sample was boiled in SDS loading buffer, subjected to
10% SDS-polyacrylamide gel electrophoresis, and
electroblotted onto a nitrocellulose membrane. Membranes were incubated with a 1:500 dilution of
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polyclonal anti-Bgn (LF-159) antibody (#ENH020-FP,
Kerafast, Boston, USA). Primary antibodies were
detected with HRP-conjugated anti-goat secondary
antibody and were developed using an ECL kit (Amersham Biosciences, Piscataway, NJ, USA).
Immunohistochemistry staining
The avidin-biotin-peroxidase complex (ABC)
Immunostaining Assay Kit (PK-6101, Vector Laboratories, Burlingame, CA) was used as previously
described [82]. Paraffin sections of bone tissue were
deparaffinized and rehydrated to unmask antigens
using sodium citrate buffer (pH 6.0) at 65°C for
2 hours for Bgn staining. Bone tissue sections were
enzymatically digested with chondroitinase ABC at
37°C for 1 hour before treated with goat normal
serum for 20 minutes at room temperature to block
non-specific background staining. The sections were
stained with anti-Bgn (LF-159) antibody (#ENH020FP, Kerafast, Boston, USA) at 1:100 dilution overnight at 4°C, followed by incubation with biotinlabeled secondary antibody and ABC Reagent for 30
minutes. Samples were washed in PBS buffer and
developed in DAB (SK4100) chromogen solution
(Vector Laboratories). Tissues were then counterstained with VECTOR Hematoxylin (H-3401) for 2
minutes at room temperature and mounted. Sections
were photographed using the Keyence microscope
(BZ-X710, Keyence, Osaka, Japan).
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were obtained using the NMR CPMG, {90°
[t  180°  t (echo)]n  TR} spin echo method,
which has a 9.5 ms wide RF-90° pulse, t of 1000ms,
and TR (sequence repetition rate) of 15s. One thousand echoes were recorded (one scan with n=1000)
to obtain the T2 profile, with 64 scans used for the
measurements. The FID signal was sampled and
recorded at 2 ms intervals using a 9.5ms wide 90° RFpulse for bound water measurements. For each FID
profile, 1500 data points were acquired in one scan
(an approximate 3ms delay window). An inversion
relaxation technique was used to invert both CPMG
and FID data to a T2 relaxation distribution spectrum.
The relative amount of bound water was then estimated as the ratio of the total intensity of bound water
signal with respect to the total intensity of the solid
form water signal (representative of bone mass) of
each sample.

Measurement of the tissue level toughness of
bone using a nanoscratch test

Low-energy NMR measurement of bound water
in bone matrix

One femur from each mouse was freshly embedded in the plastic resin (PMMA) and the cross-section of the mid-diaphysis was cut, polished, and
mounted on a custom designed specimen holder.
The average surface roughness was kept less than
80 nm. For the nanoscratch test under wet condition,
a lateral hole was drilled in the embedded specimen
and PBS solution in the chamber would fill in the
intra-medullar cavity of the femurs, thus making the
bone specimens wet throughout the testing process.
For nanoscratch test under dry condition, bone
specimens were dehydrated in a vacuum oven at
70°C for 4 hours prior to the test to remove mobile
and bound water in the tissue [9]. The nanoscratch
tests were performed on a Nano Indenter XP system
(Keysight Technologies, Santa Rosa, CA, USA) with
a cube corner diamond tip as described previously
[85,86]. A constant penetration load was set at 5 mN
and the scratch length was set at 20 mm. Test locations were randomly chosen in the middle cortex of
each specimen under a microscope attached to the
system. During the scratching, the cross-profile of
the scratch groove was measured to estimate the
width of the scratch groove. The tissue level toughness of bone was estimated using the following
equation,

The bound water was measured using a low-field
NMR technique. Based on the T2 relaxation information, the relative amount of freely mobile water, bound
water, and lattice water was assessed. Briefly, a lowfield NMR spectrometer (Bruker 20 MHz) was configured at a proton frequency of 20 MHz to assess the
amount of bound water using bone powders from the
animal models. 1H spinspin (T2) relaxation profiles

Ft L Ft
¼
V
A
where, us is the nanoscratch toughness, Ft is the lateral scratch force, L is the scratch length, V is the
volume of the scratch groove, and A is the average
cross-sectional area of the scratch groove. The
average of six measurements was used as the tissue level toughness of each bone specimen.

Alcian blue staining
For preparation of paraffin tissue sections, the femoral and tibial bones from 6-month-old male mice
were fixed in 4% paraformaldehyde for 2 days prior to
decalcification with 10% EDTA (pH 7.4) for 4 weeks.
The samples were embedded in paraffin and 5 mm
thick sections were cut onto glass slides and stained
with Alcian blue. Alcian blue staining is a semiquantitative method to measure GAG contents [83,84].
Bone sections were incubated in 3% acetic acid for 3
minutes and then incubated in 1% Alcian blue 8GX
(Sigma-Aldrich, St. Louis, MO, USA), pH 2.5, for
40 min at room temperature followed by destaining in
water and counterstained with Nuclear Fast Red
(N3020 Sigma-Aldrich, St. Louis, MO, USA).

us ¼
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Bone mineral density (BMD) measurement
Mice were anesthetized by intraperitoneal injection of 100 mg/kg of ketamine (Butler Schein, Dublin,
OH, USA) and 16 mg/kg of xylazine (Butler Schein).
We used a dual-energy X-ray absorptiometry
(DEXA) scanner, Lunar PIXImus Densitometer (GE
Medical Systems, Piscataway, NJ, USA) to measure
the BMD at pre-injection and after saline or chondroitin sulfate injection. The BMD values of the total
bones were acquired.
Bone TRAP staining for osteoclasts
Tissue sections were stained with tartrate-resistant acid phosphatase (TRAP) using Leukocyte Acid
Phosphatase Staining Kit (Sigma) according to the
manufacturer’s protocols. The NIH Image J software
was used to quantify osteoclast surface (Oc.S) and
bone surface (BS) along the endocortical surface in
the femur midshaft. The Oc.S/B.S value was then
calculated.
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Calcein and alizarin labeling, and dynamic bone
histomorphometry
Two weeks after first CS or saline injection, the
mice were subjected to an intraperitoneal injection
of calcein (Sigma) at 20 mg/kg body weight, followed
by an alizarin red S (Sigma) injection at 30 mg/kg
body weight 12 days later. Three days after the second injection, the mice were euthanized, and femurs
and tibias were dissected and embedded undecalcified in methylmethacrylate for plastic tissue sectioning. The embedded samples were cut to 8 mm
thickness tissue sections by a skiving machine
(Leica RM2265). Sections were photographed using
a Keyence microscope (BZ-X710, Keyence, Osaka,
Japan). The following bone parameters were quantified in the endocortical regions with Image J software: total perimeter (BS), single label perimeter
(sLS), double label perimeter (dLS), and distance
between labels (Ir.L.Th). The following values were
then calculated: mineralizing surface (MS/BS= [sLS/
2þdLS]/BS), mineral apposition rate (MAR = Ir.L.Th
/10), and bone formation rate (BFR/BS = MAR_
(sLS/2þdLS)/BS).
Statistical analysis
Statistical analysis was performed using GraphPad Prism5 statistics software (GraphPad). T-test
and Two-way ANOVA with post hoc Tukey test was
used for statistical analysis. Asterisks indicate the
degree of significant differences compared with the
controls, *, P < 0.05; **, P < 0.01; ***, P < 0.001.
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